Related Experiment Video
Updated: Jun 1, 2026

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response
Published on: October 3, 2019
Cutaneous reactions to adalimumab administration
M R Downes1, S Prendiville, C Kiely
1Department of Histopathology, Mater Misericordiae University Hospital, Eccles St, Dublin 7. michelle.downes@ucd.ie
Abstract:
Patients receiving antitumour necrosis factor-alpha treatment may develop cutaneous reactions. This human monoclonal antibody is used in the treatment of chronic inflammatory diseases, including arthritis and inflammatory bowel disease. A variety of side effects have been documented ranging from infection and vasculitis through to systemic lupus erythematosus and psoriasis. We report on two arthritic patients treated with adalimumab (Humira, Abbot Laboratories, IL, USA) who developed new onset rashes that resolved with discontinuation of therapy. The frequency of these cutaneous reactions has not been fully established and may benefit from a centralised registry.
Related Concept Videos
Hypersensitivity Reactions: Immune-Complex Reactions
Drug Toxicity: Allergic Reactions
Allergic Reactions: Anaphylaxis
Allergic Drug Reactions
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Hypersensitivity Reactions: Cytolytic Reactions
